Theriva Biologics, Inc.
TOVX
$1.42
$0.00780.55%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 42.43% | 7.11% | -61.01% | 5.83% | -66.16% |
| Total Depreciation and Amortization | -18.18% | -13.16% | -2.56% | 0.00% | 21.88% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -93.05% | -8.06% | 1,452.63% | 115.77% | 15.67% |
| Change in Net Operating Assets | -303.95% | -74.47% | 49,650.00% | -100.42% | -78.32% |
| Cash from Operations | -19.88% | -13.35% | 29.28% | 25.38% | -121.50% |
| Capital Expenditure | -- | 100.00% | -- | -- | 56.59% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | -- | -- | 56.59% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | -- | -- | -- |
| Issuance of Common Stock | -99.81% | 101.96% | -- | -- | 6,100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.81% | 109.59% | -- | -- | -145,800.00% |
| Foreign Exchange rate Adjustments | -823.53% | 41.67% | 131.58% | -150.00% | 790.91% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2,570.56% | 89.21% | 66.09% | 38.34% | -158.02% |